Search clinical trials for: BIA 6-512 50 mg dose

Total 263 results

Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of Food on BIA 6-512 (Trans-resveratrol)

Parkinson Disease

Portugal
Alcon Research

Completed

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration
CymaBay Therapeutics, Inc.

Completed

Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

Homozygous Familial Hypercholesterolemia

Canada, France, Netherlands, Norway
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Fundacion Clinic per a la Recerca Biomédica

Unknown

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients (EARLY-HEP-C)

Hepatitis C | HIV

Spain
The HIV Netherlands Australia Thailand Research...
Radboud University Medical Center; Bhumibol Adulyadej Hospital; Klang Hospital; Bamrasnaradura Infectious Diseases Institute and other collaborators

Recruiting

Efficacy, Safety and Pharmacokinetics of DTG With RIF

HIV/TB Coinfection

Thailand
University Health Network, Toronto

Active, not recruiting

Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (BIOTAPE)

Axial Spondyloarthritis

Canada
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

Parkinson Disease

United Kingdom
Emerald Health Pharmaceuticals

Suspended

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

United States, Australia
Kowa Research Institute, Inc.

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

Hyperlipidemia

United States
IntegoGen, LLC

Withdrawn

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Bial - Portela C S.A.

Completed

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

Parkinson Disease

Germany
University of Aarhus
Aarhus University Hospital

Completed

Does the Bioactive Substance in Coffee, Cafestol, Have Preventive Properties on Type-2-diabetes? (Acute Substudy)

Obesity, Abdominal

Denmark
Supernus Pharmaceuticals, Inc.

Withdrawn

Classroom Study of SPN-812 in Children With ADHD

ADHD
Spanish Clinical Pharmacology Society
Spanish reumatology Society

Completed

Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF (REDES-TNF)

Spondylarthropathies

Spain
PHARMENTERPRISES LLC

Completed

Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.

Healthy Volunteers

Russian Federation
Boehringer Ingelheim

Completed

Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type

Alzheimer Disease
CTI BioPharma
PPD

Recruiting

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Hepatic Impairment

United States
Fundacion para la Investigacion Biomedica del Hospital...

Completed

Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis

Cystic Fibrosis

Spain
Novo Nordisk A/S

Completed

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

Obesity

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Watson Pharmaceuticals

Completed

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

Hyperhidrosis

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
Repros Therapeutics Inc.

Completed

Extension of Study ZPV-200

Uterine Fibroids

United States
Ottawa Heart Institute Research Corporation
Heart and Stroke Foundation of Ontario

Completed

Endothelial Modulation for Angiogenic Therapy

Coronary Artery Disease

Canada
Dizal Pharmaceuticals

Completed

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

Healthy Volunteers

United States
Bial - Portela C S.A.

Completed

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

Parkinson Disease

Portugal
Laboratorios Silanes S.A. de C.V.

Completed

Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy Volunteers (NTC00940472)

Healthy

Spain
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

Chronic Hepatitis C
MediBeacon

Completed

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

Acute Kidney Injury

United States
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Healthy

Egypt
CymaBay Therapeutics, Inc.

Terminated

Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis (PBC)

Germany, United States, Canada, United Kingdom, Poland
Acer Therapeutics Inc.

Completed

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Post-menopausal Vasomotor Symptoms

United States
Lexicon Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Ardea Biosciences, Inc.

Completed

RDEA3170 PK/PD Study

Gout

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Serbia, Ukraine, United States, Czechia, Poland, Argentina, Mexico, South Africa, Chile, Bulgaria, Colombia, Russian Federation
Janssen Research & Development, LLC

Terminated

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

Healthy

Belgium
Novartis

Completed

Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy

Type 2 Diabetes Mellitus

China
Chong Kun Dang Pharmaceutical

Completed

To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors

Dyslipidemias

Australia
Milton S. Hershey Medical Center
American Heart Association

Not yet recruiting

Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion

Peripheral Artery Disease | Ischemia Reperfusion Injury
Medical College of Wisconsin

Withdrawn

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma
U.S. Army Medical Research and Development Command

Completed

Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population (APCG)

Gingivitis | Plaque

United States
The Netherlands Cancer Institute
Roche Pharma AG; Borstkanker Onderzoek Groep

Active, not recruiting

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (TRAIN-2)

Breast Cancer | HER2 Positive

Netherlands
The Lymphoma Academic Research Organisation
French Innovative Leukemia Organisation

Completed

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (T³)

Mantle Cell Lymphoma Refractory

France
Amgen

Completed

Pegfilgrastim PBPC Mobilization Study

Lymphoma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Oncology | Hematology
McMaster University
MediPharm Labs Corp

Withdrawn

Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study

Generalized Anxiety Disorder | Social Anxiety Disorder | Panic Disorder | Agoraphobia

Canada
Estetra

Completed

E4/DRSP Single and Multiple Dose PK and Early QT Study

Contraception

3

Subscribe